Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Advanced Solid Tumor 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Bosentan × 1 year × Clear all
NCT01009177 2026-06-03

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Actelion

Phase 2 Completed
80 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT04158635 2026-04-17

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

City of Hope Medical Center

Phase 1 Recruiting
21 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05072106 2025-09-16

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

PharmaMar

Phase 1 Completed
11 enrolled 26 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡